As a result of an error in absolute numbers and units, the number of plaques in Figure 2B refers to an arbitrary area taken during each measurement and does not reflect 1 mm 2 . The corrected version of the figure and figure legend are shown below. The correction does not affect the conclusions of the paper. The authors apologize for any confusion caused by this error. (A) Representative amyloid staining (using thioflavin S) and Ab staining (using the antibody 6E10) of female hAPP mouse cortices at 6.5 months of age following placebo and CP-113,818 treatments. Ab staining of cortices at day 0 (at 4 months of age) without and, at day 57, with CP-113,818 treatment was remarkably similar, suggesting that the ACAT inhibitor prevented formation of amyloid pathology in these mice. (B, corrected) Quantitative analysis of brain plaque load, as assessed by number of plaques per mm 2 stained with the Ab-specific antibody 6E10. In the hAPP animal model, the cortex is the first to develop amyloid pathology, followed by the hippocampus. Therefore, at 6.5 months of age, males exhibit distinct AD pathology in the cortex but not in the hippocampus. CP-113,818 reduced cortical plaque number by 89%, similarly in females (89%) and males (97%). The most marked effect was observed in the hippocampus of female mice, where amyloid load was decreased by 98%, p < 0.0000004.
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